Can-Fite BioPharma CANF
NYSE CANF
$2.21 +0.03 (+1.61%)
As of: Sep 30, 2026 · 3:58 PM EDT

Can-Fite BioPharma (CANF) Share-based Compensation (2013)

Updated

Can-Fite BioPharma (CANF) reported Share-based Compensation of $340,000 for FY2025, down 6.1% from $362,000 in FY2024.

Analysis

Can-Fite BioPharma (CANF) Share-based Compensation (2013) Analysis & Trends

Dating back to FY2015, Can-Fite BioPharma's Share-based Compensation record includes 11 years.

  • Share-based Compensation has a five-year compound annual growth rate of -0.9% (FY2020 to FY2025).
  • Five-year annual Share-based Compensation spans a low of $261,000 in FY2023 and a high of $466,000 in FY2021.
  • According to Business Quant data, Share-based Compensation came in at $362,000 in FY2024 (+38.7%), $261,000 in FY2023 (-0.8%), $263,000 in FY2022 (-43.6%) and $466,000 in FY2021 (+31.3%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 458.00 Mn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 166.00 Mn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 298.00 Mn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 165.00 Mn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 231.00 Mn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 249.00 Mn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 170.20 Mn
10 Can-Fite BioPharma 1.82 Mn -17.88 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2013 194,000.00
API Access

Can-Fite BioPharma Share-based Compensation API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=share-based-compensation&ticker=CANF&period=max&api_key=YOUR_API_KEY